Wei Zhang

Dr. Wei Zhang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BMBingqi Ma
Bingqi Ma
HMHuijuan Meng
Huijuan Meng
YTYe Tian
Ye Tian
YWYingying Wang
Yingying Wang
TSTianqiang Song
Tianqiang Song
QLQiang Li
Qiang Li
Background: Isocitrate dehydrogenase 1/2 (IDH1/2), BAP1, ARID1A and PBRM1 have been reported as the most frequent mutant genes in intrahepatic cholangiocarcinoma (ICC), and their relationships with clinicopathological features and prognosis were researched in this study. Methods: We collected clinical data of 130 ICC patients from January 2012 to December 2017. The IDH1/2 mutation and loss of BAP1, ARID1A and PBRM1 expressions were detected by DNA sequencing or immunohistochemical methods, and histological subtype of ICCs was determined by hematoxylin-eosin, Alcian blue and S100P staining. Results: IDH1/2 mutation was related to decreased preoperative serum total bilirubin (P = 0.039), ferritin (P = 0.000) and higher histological differentiation (P = 0.024), and was associated with prolonged disease-free survival (P = 0.009) and a trend toward increased overall survival (P = 0.126) in small duct type of ICCs. Immunohistochemical staining results of MsMab-1 were generally consistent with DNA sequencing for IDH1/2 mutant in ICCs (κ = 0.691). Only BAP1 expression loss was correlated to prolonged disease-free survival (P = 0.031) and overall survival (P = 0.041) in large duct type of ICCs. Conclusions: IDH1/2 mutation is a favorable predictor and may be related to iron metabolism in small duct type of ICCs. Furthermore, we suggest that the detection of IDH1/2 mutation is indispensable to determine targeted therapy in small duct type ICCs, while it is not necessary in large duct of ICCs. MsMab-1 is a relatively effective multi-specific antibody against IDH1/2 mutant in ICCs. BAP1 expression loss was correlated with improved prognosis only in large duct type ICCs.

31 October 2020 in BioScience Trends
Verified
Journal Article
Closed access
PDF file
WZWei Zhang
Wei Zhang
HZHongyuan Zhou
Hongyuan Zhou
YWYingying Wang
Yingying Wang
ZZZewu Zhang
Zewu Zhang
GCGuangtai Cao
Guangtai Cao
QLQiang Li
Qiang Li
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

23 October 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
WZWei Zhang
Wei Zhang
JSJunping Shi
Junping Shi
YWYingying Wang
Yingying Wang
HZHongyuan Zhou
Hongyuan Zhou
ZZZewu Zhang
Zewu Zhang
QLQiang Li
Qiang Li

12 August 2014 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
WZWei Zhang
Wei Zhang
TSTian-Qiang Song
Tian-Qiang Song
TZTi Zhang
Ti Zhang
QWQiang Wu
Qiang Wu
DKDa-Lu Kong
Da-Lu Kong
HSHui-Chuan Sun
Hui-Chuan Sun
Adjuvant interferon (IFN) therapy following curative treatment for hepatocellular carcinoma (HCC) has been extensively investigated; however, the clinical benefits with different hepatitis backgrounds remain unclear. Medline, Embase, PubMed and the Cochrane Library databases were searched to identify randomized trials and cohort studies that enrolled HCC patients who received curative surgery or ablation therapy followed by IFN and control subjects; the studies were required to include data on early or late recurrence and mortality rates of HCC. Hepatitis B virus (HBV) associated with HCC (HBV-HCC) and hepatitis C virus (HCV) associated with HCC (HCV-HCC) were separately analyzed and recurrence, mortality and clinicopathological factors were compared. A total of 14 studies (9 randomized trials and 5 cohort studies, including 1,385 patients in total) were eligible for meta-analysis. IFN was found to decrease mortality and early recurrence rates, but exerted no effect on late recurrence rate. The effect of IFN differed between HBV-HCC and HCV-HCC cases. In HCV-HCC, IFN significantly reduced mortality as well as recurrence rates. However, in HBV-HCC patients, IFN reduced mortality rather than recurrence rates, although it also reduced the recurrence rate in certain subgroups. In conclusion, the effect of adjuvant IFN on postoperative recurrence differed between HBV-HCC and HCV-HCC cases; therefore, different strategies with adjuvant IFN should be used to treat HCC with different hepatitis backgrounds.

11 February 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
WZWei Zhang
Wei Zhang
JSJunping Shi
Junping Shi
RLRentao Li
Rentao Li
ZHZhiqiang Han
Zhiqiang Han
LLLing Li
Ling Li
QLQiang Li
Qiang Li
Here, we report a case of postoperative recurrence of gallbladder carcinoma (GBC) in a patient who declined systemic chemotherapy. ATM S1905Ifs*25 and STK11 K262Sfs*25 mutations were detected by next-generation sequencing. Oral administration of olaparib was initiated. One month later, the patient experienced relief of clinical symptoms, a decrease in CA19-9 level, and a reduction in abnormal signal in the subcapsular region. The tumor response remained stable for approximately 13 months. This is the first case to demonstrate the clinical benefits of olaparib treatment in a patient with GBC harboring an ATM-inactivating mutation. This observation helps to better inform treatment options to enhance the care of patients with advanced GBC. Key Points: A patient with gallbladder carcinoma harboring an ATM-inactivating mutation responded to olaparib with a progression-free survival of 13 months. This is the first report that demonstrates the clinical benefits of olaparib treatment in a patient with gallbladder carcinoma with an ATM-inactivating mutation. It also highlights the importance of next-generation sequencing, which can provide valuable information for planning effective targeted therapies for gallbladder carcinoma. Evidence-based decisions help determine the best choice of treatment for individualized patient care.

8 July 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
XDXiang Dong
Xiang Dong
ZZZewu Zhang
Zewu Zhang
QZQin Zhang
Qin Zhang
LCLu Chen
Lu Chen
GCGuangtai Cao
Guangtai Cao
WZWei Zhang
Wei Zhang